Capricor FDA Decision Watch | Business and Finance News

Capricor Therapeutics’ General Counsel Karen Krasney dumped 24K shares worth $732K just before a stock dip—though she exercised options first, the move signals caution. The biotech, up 200% last year but down 30% this year, still burns cash but has runway to 2027. The real focus? The looming FDA decision on their Duchenne muscular dystrophy treatment Deramiocel, with a decision expected August 22. Analysts are bullish—if approved, it could ignite the stock after this pullback. This insider sale? Just one data point in a high-stakes bet on science and regulatory wins. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/bfc677217b7c0e10